Neuronal Nogo-A regulates glutamate receptor subunit expression in hippocampal neurons. 2011

Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
Department of Neurology, University of Michigan and VA Ann Arbor Healthcare System, Ann Arbor, Michigan 48109, USA.

Nogo-A and its cognate receptor NogoR1 (NgR1) are both expressed in neurons. To explore the function of these proteins in neurons of the CNS, we carried out a series of studies using postnatal hippocampal neurons in culture. Interfering with the binding of Nogo-A to NgR1 either by adding truncated soluble fragment of NgR1 (NgSR) or by reducing NgR1 protein with a specific siRNA, resulted in a marked reduction in Nogo-A expression. Inhibition of Rho-ROCK or MEK-MAPK signaling resulted in a similar reduction in neuronal Nogo-A mRNA and protein. Reducing Nogo-A protein levels by siRNA resulted in an increase in the post-synaptic scaffolding protein PSD95, as well as increases in GluA1/GluA2 AMPA receptor and GluN1/GluN2A/GluN2B NMDA glutamate receptor subunits. siRNA treatment to reduce Nogo-A resulted in phosphorylation of mTOR; addition of rapamycin to block mTOR signaling prevented the up-regulation in glutamate receptor subunits. siRNA reduction of NgR1 resulted in increased expression of the same glutamate receptor subunits. Taken together the results suggest that transcription and translation of Nogo-A in hippocampal neurons is regulated by a signaling through NgR1, and that interactions between neuronal Nogo-A and NgR1 regulate glutamatergic transmission by altering NMDA and AMPA receptor levels through an rapamycin-sensitive mTOR-dependent translation mechanism.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D009185 Myelin Proteins MYELIN-specific proteins that play a structural or regulatory role in the genesis and maintenance of the lamellar MYELIN SHEATH structure. Myelin Protein,Protein, Myelin,Proteins, Myelin
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003712 Dendrites Extensions of the nerve cell body. They are short and branched and receive stimuli from other NEURONS. Dendrite
D004622 Embryo, Mammalian The entity of a developing mammal (MAMMALS), generally from the cleavage of a ZYGOTE to the end of embryonic differentiation of basic structures. For the human embryo, this represents the first two months of intrauterine development preceding the stages of the FETUS. Embryonic Structures, Mammalian,Mammalian Embryo,Mammalian Embryo Structures,Mammalian Embryonic Structures,Embryo Structure, Mammalian,Embryo Structures, Mammalian,Embryonic Structure, Mammalian,Embryos, Mammalian,Mammalian Embryo Structure,Mammalian Embryonic Structure,Mammalian Embryos,Structure, Mammalian Embryo,Structure, Mammalian Embryonic,Structures, Mammalian Embryo,Structures, Mammalian Embryonic
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
November 1988, Proceedings of the National Academy of Sciences of the United States of America,
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
August 1996, The European journal of neuroscience,
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
January 2003, Neuroscience,
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
April 2003, Journal of neuroscience research,
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
August 1993, Molecular pharmacology,
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
January 2010, The Journal of biological chemistry,
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
January 2012, Proceedings of the National Academy of Sciences of the United States of America,
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
April 2022, Pharmaceuticals (Basel, Switzerland),
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
January 1993, The Japanese journal of physiology,
Xiangmin Peng, and Jeeyong Kim, and Zhigang Zhou, and David J Fink, and Marina Mata
January 2015, Frontiers in cellular neuroscience,
Copied contents to your clipboard!